Streetbeat News

Products Services

ALIM

Alimera Sciences, Inc. (NASDAQ:ALIM) announces that clinical data for ILUVIEN and YUTIQ will be featured in five presentations during the Retina Society's 56th Annual Scientific Meeting. Both ILUVIEN and YUTIQ are sustained release intravitreal implants used to treat diabetic macular edema (DME) and chronic non-infectious uveitis respectively.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:07 pm

BNRG

Brenmiller Energy (NASDAQ:BNRG) has signed a contract with Tempo, partially owned by Heineken International, to replace the beverage manufacturer's heavy fuel oil boilers at its plant in Netanya, Israel, with Brenmiller's bGen™ ZERO thermal energy storage system. The system will produce sustainable process steam using solar photovoltaic energy and off-peak grid power. Brenmiller estimates that the project will eliminate the use of approximately 2,000 tons of heavy fuel oil annually and mitigate over 6,200 tons of carbon emissions each year. The project is expected to be completed by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:07 pm

BAH

Booz Allen Hamilton (NYSE:BAH) has announced new insights from its AI portfolio, doubling down on its role in deploying AI for the federal government. The firm has been recognized as the largest provider of AI-related services to the federal government. It has scaled its AI portfolio to offer new, specialized AI technology stacks. The firm has nearly 200 active AI projects across defense, national security, and civil missions.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:05 pm

DXR

Daxor Corporation (NASDAQ:DXR) has announced new data from Banner University Medicine validating the benefits of the company's BVA-100 diagnostic blood test for ambulatory patients with advanced heart failure. The data was presented at the Annual Scientific Meeting of the Heart Failure Society of America. The study found that the BVA-100 test provided highly effective guidance for care of heart failure patients, with the test identifying variances in red blood cell volumes that provided an opportunity to evaluate and treat these patients.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:04 pm

TPST

Tempest Therapeutics has announced updated results from an ongoing Phase 1B/2 study of TPST-1120 combination, showing clinical superiority in multiple endpoints compared to Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:04 pm

NVAX

Novavax, Inc. (NASDAQ:NVAX) will present study findings at IDWeek 2023 and World Vaccine Congress Europe 2023. The presentations will include clinical data on Novavax's BA.1, BA.5 and bivalent variant vaccines, an evaluation of its prototype COVID-19 vaccine in children aged 6 to 11 years, real-world evidence on adverse events post-COVID vaccination and an update on its COVID-19-Influenza Combination (CIC) vaccine candidate.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:03 pm

PDSB

PDS Biotechnology Corporation (NASDAQ:PDSB) has announced interim safety and immune response data from a Phase 1/2 clinical trial for PDS0301, a novel investigational tumor-targeting, antibody-conjugated Interleukin 12, in combination with docetaxel, to treat metastatic prostate cancer. The data will be presented at the 11th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2023) in Athens, Greece.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:03 pm

ALUR

Allurion Technologies, Inc. (NYSE:ALUR) has completed patient enrollment in its AUDACITY trial, which is designed to support FDA approval of the Allurion Balloon, a novel weight loss device. The trial enrolled 550 patients at 17 sites and completed enrollment two months ahead of schedule. The Allurion Balloon is a swallowable, procedure-less gastric balloon for weight loss.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:03 pm

GE

SOFIE Biosciences and GE HealthCare have entered into a global licensing agreement for the development and commercialization of SOFIE's two investigational radiopharmaceutical diagnostics. GE HealthCare will take on global rights for [68Ga]FAPI-46 and outside-US rights for [18F]FAPI-74, both currently in Phase II clinical trials. SOFIE will maintain clinical development and commercialization rights for [18F]FAPI-74 in the U.S.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:02 pm

VIR

Vir Biotechnology, Inc. (NASDAQ:VIR) has announced that eight abstracts from its chronic hepatitis B and chronic hepatitis delta clinical programs have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting in November 2023. The presentations include seven poster presentations and one late-breaking oral presentation.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:02 pm